Evidence map›Paper›PMID 41214803›Full record

ArticleAlzheimer's research & therapy2025

Polygenic pathways shape white matter vulnerability to Alzheimer's disease-related pathophysiological changes.

Mario Tranfa, Leonard Pieperhoff, Giuseppe Pontillo, Emma S Luckett, Lyduine E Collij, Tiago Gil Oliveira, Niccoló Tesi, Natalia Vilor-Tejedor, André Altmann, Luca Roccatagliata and 15 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Mario TranfaDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands. m.tranfa@amsterdamumc.nl.
Leonard PieperhoffDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Giuseppe PontilloDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Emma S LuckettDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Lyduine E CollijDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Tiago Gil OliveiraLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus Gualtar, Braga, 4710-057, Portugal.
Niccoló TesiGenomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC location VUmc, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Natalia Vilor-TejedorBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Calle Wellington 30, Barcelona, 08005, Spain.
André AltmannDepartment of Medical Physics, UCL Hawkes Institute, University College London, 90 High Holborn, London, WC1E 6BT, UK.
Luca RoccatagliataIRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, Genoa, 16132, Italy.
Matteo PardiniIRCCS Ospedale Policlinico San Martino, Largo Rosanna Benzi 10, Genoa, 16132, Italy.
Henne HolstegeGenomics of Neurodegenerative Diseases and Aging, Human Genetics, Amsterdam UMC location VUmc, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Marcel ReindersDelft Bioinformatics Lab, Delft University of Technology, Van Mourik Broekmanweg 6, Delft, 2628 XE, Netherlands.
Pierre PayouxDepartment of Nuclear Medicine, Toulouse University Hospital, 2 Rue Charles Viguerie, Toulouse, 31300, France.
Pablo Martinez-LageCentro de Investigación y Terapias Avanzadas, Neurología, CITA-Alzheimer Foundation, , Mikeletegi Pasealekua, 71, 1, Donostia, San Sebastián, 20009, Spain.
Craig W RitchieOutpatient Department 2, Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, Western General Hospital, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XU, UK.
Adam WaldmanCentre for Clinical Brain Sciences, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.
Joanna M WardlawCentre for Clinical Brain Sciences, The University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.
Juan Domingo GispertBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Calle Wellington 30, Barcelona, 08005, Spain.
Gemma SalvadóDepartment of Clinical Sciences, Clinical Memory Research Unit, Lund University, St Johannesgatan 8, Malmö, 211 46, Sweden.
Arturo BrunettiDepartment of Advanced Biomedical Sciences, University of Naples "Federico II", Via Pansini 5, Naples, 80131, Italy.
Henk J M M MutsaertsDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Alle Meije WinkDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.
Luigi LorenziniDepartment of Radiology and Nuclear Medicine, Amsterdam UMC location VUmc Amsterdam, De Boelelaan 1117, Amsterdam, 1081 HV, Netherlands.

Funding

Alzheimer Association Research Fellowship 23AARF-1029663Dutch Heart Foundation 03-004-2020-T049EU/EFPIA Innovative Medicines Initiative (IMI) 115736MSCA postdoctoral fellowship 101204296State Research Agency grant RYC2022-038136-I
6 · The paper itself

Abstract

backgroundThe accumulation of amyloid-β

methodsWe selected 803 individuals (mean age = 64.7 ± 7.3 years, 458 [57.0%] females, 275 [34.2%] APOE-ε4 carriers) with CSF-Aβ

resultsP-Tau

conclusionsPathway-specific genetic vulnerability to AD is associated with alterations in WM tracts both directly and by moderating the effects of AD-related pathophysiological changes. AD-associated genetic risk should be integrated into the AD diagnostic framework to enable targeted screening and intervention for future preclinical trials aimed at specific biological pathways.

Indexed as

Alzheimer DiseaseMultifactorial InheritanceWhite MatterAgedAmyloid beta-PeptidesCohort StudiesFemaleHumansMaleMiddle AgedPeptide FragmentsPhosphorylationtau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide Fragmentstau ProteinsAlzheimer’s diseaseDiffusion magnetic resonance imagingFixel-based analysisPolygenic pathwaysPolygenic risk scoresWhite matter

Identifiers

PMID41214803
PMCPMC12604407

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.